Annovis Bio, Inc. (ANVS) · Oct 30, 2026 · Delisting

Annovis NYSE warning puts pivotal trial funding under pressure

NYSE deficiency notice — $48.4M 30-day market cap vs $50M threshold; $4.3M stockholders’ deficit

Annovis received an NYSE deficiency notice as its Phase 3 biotech program approaches pivotal Alzheimer’s data and NDA preparation.

Annovis is a capital-constrained, Phase 3 biotech moving its lead drug buntanetap toward pivotal Alzheimer’s data and eventual NDA preparation; its pivotal Alzheimer’s trial reached full enrollment in July, and the company has since been preparing for the next development milestone.

The filing adds a real listing and financing constraint. Annovis received an NYSE notice because its 30-trading-day average market capitalization fell below the $50 million requirement while stockholders’ equity was also below $50 million. The filing gives the shortfall as approximately $48.4 million of average market capitalization and a $4.3 million stockholders’ deficit. 〔0〕

MetricFiling figureStandard / deadline
30-day average market capitalization (Notice)$48.4M$50M minimum
Stockholders’ equity (June 30, 2026)$(4.3)MLess than $50M
Compliance planWithin 45 days9-month cure period
Abnormally low trading level—Generally below $0.10

The immediate consequence is procedural, not an operating shutdown. The stock remains listed during the cure process if the NYSE accepts the company’s plan, but the added “.BC” designation publicly flags the deficiency. 〔1〕

The bigger issue is capital flexibility while the company is approaching a costly clinical and regulatory stretch. The filing says operations and reporting obligations continue normally, but restoring equity and market capitalization may require actions that affect financing terms, ownership, or the timeline for advancing buntanetap. The company has 45 days from the October 29 notice to submit a plan, and the NYSE can begin delisting proceedings if the plan is late, rejected, or ultimately unsuccessful. 〔2〕

Bottom line: This does not halt Annovis’s Phase 3 program today, but it turns a visible financial weakness into a formal exchange-compliance problem. The next meaningful test is whether the NYSE accepts a credible plan to restore compliance before pivotal data and NDA work demand more capital. Cite filing: 〔3〕

What to watch next

NYSE compliance plan submission, by December 13, 2026

Original filing on SEC EDGAR

More Annovis Bio, Inc. news

Annovis NYSE warning puts pivotal trial funding under pressure | ANVS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.